[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyspnea-asthmatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyspnea-asthmatic":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100508636","diaphragmatic-function-as-a-biomarker-100508636",false,"NCT05903001","Diaphragmatic Function as a Biomarker","Diaphragmatic Function as a Biomarker in Patients With Respiratory Diseases","DFUNBIO","Inclusion Criteria:\n\n* patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension\n* is 18 years or older\n* is mentally and physically able to understand the study and to follow instructions\n* are legally competent\n* signed declaration of consent\n\nExclusion Criteria:\n\n* BMI \\> 35\n* current or treatments or diseases in the past which could influence the evaluation of the study\n* Expected lack of willingness to actively participate in study-related measures\n* alcohol or drug abuse\n* disc herniation\u002Fprolapse\n* epilepsy\n* wheelchair bound\n* in custody due to an official or court order\n* in a dependent relationship or employment relationship with investigating physician or one of their deputy\n* emergency inpatient hospital stay within 4 weeks before study-specific examinations","ALL","18 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.",[25,26,27,28,29,30],"Dyspnea; Asthmatic","COPD","Fibrosis","Pulmonary Hypertension","Asthma","Dyspnea",[32,26,33,34,35,36],"dyspnea","asthma","fibrosis","pulmonary hypertension","pneumology","RECRUITING","2026-01-26",{"date":40,"type":41},"2026-01-28","ACTUAL",{"date":43,"type":41},"2023-07-01",{"date":45,"type":21},"2026-12-30",{"name":47,"class":48},"RWTH Aachen University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100583020","impact-of-sarcopenia-on-dyspnea-in-patients-with-asthma-100583020","NCT06870890","Impact of Sarcopenia on Dyspnea in Patients With Asthma","MUDYSA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient affiliated to a social security scheme.\n* Patient capable of giving free, informed, written and signed consent.\n* Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment\n* ACT asthma control score \\\u003C 20\n* Patient judged by the investigator to be able to to perform a maximal exercise test.\n\nExclusion Criteria:\n\n* Patient under guardianship\u002Ftrusteeship\u002Fsupervision of justice\n* Pregnant or breast-feeding women\n* Unstable heart disease\n* Patients who have been smoking or have stopped smoking for less than 5 years,",{"count":58,"type":21},100,"INTERVENTIONAL",[61],"NA","Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.\n\nThe impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .\n\nThe morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.\n\nThe investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.",[64,29,30,25,65,66,67,68],"Sarcopenia","Cytokines","Adipokines","Myokine","Muscle Disorder",[29,64,30],"NOT_YET_RECRUITING","2025-03-10",{"date":73,"type":41},"2025-03-11",{"date":75,"type":21},"2025-03-25",{"date":77,"type":21},"2026-10",{"name":79,"class":48},"University Hospital, Clermont-Ferrand",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":59,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100575487","effects-of-a-pulmonary-and-cardiovascular-rehabilitation-program-100575487","NCT06772922","Effects of a Pulmonary and Cardiovascular Rehabilitation Program","Inclusion Criteria:\n\n* Candidates for the pulmonary rehabilitation program: users diagnosed with chronic obstructive pulmonary disease (COPD), pulmonary emphysema, pulmonary fibrosis, asthma or other lung disease.\n* Candidates for the cardiovascular rehabilitation program: users diagnosed with acute myocardial infarction, myocardial revascularization surgery, coronary angioplasty, stable angina, valve replacement, chronic heart failure and who meet the criteria for phase III of cardiovascular rehabilitation.\n* Referral with medical clearance for rehabilitation\n\nExclusion Criteria:\n\n* Patients with any contraindication to aerobic or muscle-strengthening physical exercise, such as significant arrhythmias, untreated heart disease, myocarditis, recent or untreated pulmonary embolism, and uncontrolled systemic arterial hypertension, among other conditions.",{"count":87,"type":21},26,[61],"Non-communicable chronic diseases (NCDs) affect approximately 30% of the adult global population, significantly impacting respiratory function and quality of life. Pulmonary and cardiovascular rehabilitation has proven to be an effective therapeutic intervention for managing respiratory symptoms and cardiovascular and improving functional capacity in patients with chronic respiratory conditions. The objective of this study is to evaluate the effects of the pulmonary and cardiovascular rehabilitation program on users of the physical therapy service of CECOM of UNICAMP related to functional capacity, quality of life and respiratory variables after 3 months of the program. Candidates for the pulmonary rehabilitation program are users diagnosed with chronic obstructive pulmonary disease (COPD), pulmonary emphysema, pulmonary fibrosis, asthma or other lung disease. Candidates for the cardiovascular rehabilitation program are users diagnosed with: infarction (AMI), myocardial revascularization surgery, coronary angioplasty, stable angina, valve replacement, chronic heart failure and who meet the criteria for phase III of cardiovascular rehabilitation. They should be referred to physical therapy by the cardiologist with complementary exams and exercise test. The program's assessment will consist of: anamnesis, analysis and recording of complementary exams, physical assessment (weight, height, BMI, cardiac and pulmonary auscultation, blood pressure, heart rate, peripheral oxygen saturation, respiratory muscle strength), functional capacity (six-minute walk test) and quality of life (questionnaire). The program will include aerobic exercises on a treadmill or stationary bike with an intensity between 50-70% of the reserve HR, below the ischemic thresholds. It will also include peripheral muscle strength exercises for the upper and lower limbs, in addition to respiratory muscle training for lung disease patients.",[91,92,25,93,30],"Respiratory Muscle Weakness","Quality of Lifte","Dyspnea; Cardiac",[95,96,97,98],"pulmonary rehabilitation","Non-communicable chronic diseases","cardiovascular disease","cardiac rehabilitation","2025-01-11",{"date":101,"type":41},"2025-01-14",{"date":103,"type":41},"2019-03-03",{"date":105,"type":21},"2025-12-20",{"name":107,"class":48},"University of Campinas, Brazil"]